<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment with bevacizumab, an antiangiogenic agent, in patients with metastatic or unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> was approved less than 4 years ago in Japan </plain></SENT>
<SENT sid="1" pm="."><plain>Bevacizumab improves the survival of patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>; however, it may lead to complications such as <z:mp ids='MP_0001914'>bleeding</z:mp>, which are sometimes fatal </plain></SENT>
<SENT sid="2" pm="."><plain>Bevacizumab should be administered only after careful consideration because the potential risks of therapy outweigh its benefits </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, pharmaceutical companies do not recommend bevacizumab therapy for patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>While some reports support the cautious use of bevacizumab, others report that it is not always necessary to prohibit its use in patients with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> to the central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>), including the brain </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, bevacizumab therapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> is controversial, and it is unclear whether <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> are a risk factor for <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> during anti-vascular endothelial growth factor (VEGF) therapy </plain></SENT>
<SENT sid="6" pm="."><plain>We report a 64-year-old man and a 65-year-old man with <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> without <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e>; these patients developed multifocal and solitary <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo>, respectively, after the administration of bevacizumab </plain></SENT>
<SENT sid="7" pm="."><plain>Our findings suggest that <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> can occur even if the patient does not have <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> prior to bevacizumab treatment and also suggest that <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> are not a risk factor for <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> with bevacizumab treatment </plain></SENT>
<SENT sid="8" pm="."><plain>These findings also question the necessity of excluding patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> from clinical trials on anti-VEGF therapy </plain></SENT>
</text></document>